Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Salmon Evolution Holding ASA: Results for the first quarter 2021

First quarter highlights · Construction of Phase 1 at Indre Harøy progressing according to plan, on time on budget · Formalized K Smart joint venture with Dongwon Industries in South Korea · Successful private placement of NOK 500 million · Converted to ASA - Process for up-listing to Oslo Stock Exchange main list started · Available cash of NOK 1 billion (NOK 3.35 per share) on 31 March 2021   Subsequent events · Signed term sheet for NOK 625 million bank financing with Nordea, Sparebanken Vest and GIEK on very competitive terms, securing a funding for Indre

Neste, Mitsui Chemicals and Toyota Tsusho collaborate to start Japan's first production of renewable plastics from 100% bio-based hydrocarbons

Neste Corporation, Press Release, 20 May 2021 at 8 a.m. (EET) Neste, Mitsui Chemicals, Inc. and Toyota Tsusho Corp. announced today that they are joining forces to enable Japan’s first industrial-scale production of renewable plastics and chemicals from 100% bio-based hydrocarbons.In this collaboration, Mitsui Chemicals will use Neste RE™ , 100% bio-based hydrocarbons produced by Neste, to replace a part of the fossil feedstock in the production of a variety of plastics and chemicals at its crackers within Osaka

Interim report January – March 2021

Curasight A/S (“Curasight” or “the Company”) hereby publishes the interim report for the period January 1 – March 31, 2021. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: “Curasight accomplished essential milestones during the first quarter by being granted two patents, one in the US and one in Canada. Results from a phase II study in prostate cancer patients conducted by researchers at Rigshospitalet were published in the March issue of the Journal of Nuclear

2cureX’s clinical partner, University Hospital Vejle, presents positive results of the IndiTreat®-guided clinical trial in third line metastatic colorectal cancer at the ASCO 2021 Annual Meeting

Copenhagen — May 20, 2021 — 2cureX announces that the outcome of the clinical trial (NCT03251612, TICC) is published by ASCO prior to its Annual Meeting in June 2021. The primary endpoint of the trial was met.The patients enrolled in the trial suffered from end stage metastatic colorectal cancer and had IndiTreat®-guided third line treatment selected from a panel of 15 drug regimen. They comprised standard cytostatics and other cancer drugs with proven effect in clinical trials.  The primary endpoint was Progression Free Survival (PFS)

First day to exercise Catena Media’s warrants (CTM TO1) for subscription of new shares during the fifth exercise period

Catena Media plc (Nasdaq Stockholm: CTM)  Catena Media plc (“Catena Media” or the “Company”) today announces that the fifth period to subscribe for shares in the Company by exercise of warrants (ticker CTM TO1) (the “Warrants) commences today, 20 May 2021. The fifth period to subscribe for shares in the Company by exercise of Warrants commences today, 20 May 2021, and runs up to and including 29 May 2021. During this period, each Warrant entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 18.90. Payment of subscribed shares can be made

BERGENBIO TO PRESENT DATA FROM PHASE I/II BEMCENTINIB/ERLOTINIB COMBINATION TRIAL IN NSCLC AT ASCO MEETING

Bergen, Norway, 20 May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will present an end-of-trial update from a Phase I/II study of bemcentinib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) Annual Meeting. End of trial data showed that bemcentinib in combination with erlotinib is both feasible and tolerable in patients with NSCLC. Benefit was seen in a subset of patients who either

Mercell Q1 2021: Announces continued strong growth and high growth ambitions

Continuing the expansion • Entering European expansion phase with acquisition of Negometrix • Acquisition funding secured through NOK 434 million equity issue in February 2021 • Acquisitions of CTM Solutions in the Netherlands and Ibistic in Denmark in May, financed with cash in hand Solid financial performance • ARR of NOK 634 million per Q1, +170% year-on-year with organic growth of +28% • Reported revenue +160% to NOK 148.2 million in Q1 (57.0), with EBITDA of NOK 35.4 million (6.8) • 27% EBITDA-margin adjusted for special items Ambitious long-term strategy •

Change in the YIT Management Team

YIT Corporation  Stock Exchange Release  20 May 2021 at 8:00 a.m.Change in the YIT Management Team YIT Corporation's Board of Directors has appointed Pasi Tolppanen (54, Ph.D., Engineering Geology) as the Executive Vice President of Infrastructure segment and a member of the Group Management Team. He shall take over his position latest at the beginning of September 2021. Pasi Tolppanen is currently working as a CEO of DEN Group. Prior to his current position, he has worked as a CEO of Maintpartner Group and a President of Regional Operations Northern Europe of Pöyry Plc and Managing

Webstep ASA: First quarter results 2021

Oslo 20 May 2021: Webstep ASA reports revenue of NOK 194.2 million and EBIT of NOK 18.1 million for the first quarter, up 6.1 percent and 38.5 percent from the same period last year. A three year framework agreement with Equinor of approximately NOK 85 million was signed in February.Webstep recorded revenues in the first quarter of NOK 194.2 million, up from NOK 183.0 million in the first quarter last year. Revenue growth was driven by increased headcount, higher utilization and higher hourly rates. EBIT for the first quarter amounted to NOK 18.1 million, up from NOK 13.1 million in the

Must-Read This Paddy Power Bingo Review Before Signing Up

Paddy Power Bingo  is the offshoot of the main Paddy Power sports betting site. It’s run by the same company, which means you can expect hilarious marketing campaigns, lots and lots of great promotions - and a huge amount of fun. We signed up to it and got involved with the bingo madness. We played the games, checked the rooms out and grabbed the welcome offer. What did we think of it? Find out in our Paddy Power Bingo review! Brews at the ready, eyes down … let’s go!PROS · Excellent welcome bonus · Action-packed games ·

Hexagon Purus signs multi-year global agreement for Type 4 hydrogen cylinders

Hexagon Purus has signed a global supply agreement with Air Liquide, a world leader in gases, technologies and services for Industry and Health. The agreement covers the supply of Type 4 hydrogen cylinders to the Group and their affiliates around the world. The cylinders will be used for transport of hydrogen for industry and mobility. The global agreement designates Hexagon Purus as a long-term partner. Hexagon Purus plans to pursue further opportunities within the Group, and in conjunction has already entered its first local supply agreement with an Air Liquide affiliate in a key

Embracer Group publishes Full Year Report and Q4, January-March 2021: OPERATIONAL EBIT INCREASED 216% to SEK 903 MILLION

FOURTH QUARTER, JANUARY–MARCH 2021 (Compared to JANUARY–MARCH 2020) > Net sales increased by 80% to SEK 2,404.2 million (1,339.1). > Net sales of the Games business area increased by 119% to SEK 1,975.2 million (903.5). THQ Nordic SEK 354.6 million (306.7), Deep Silver SEK 464.9 million (514.7), Coffee Stain SEK 780.9 million (82.1), Saber Interactive SEK 270.7 million (-) and DECA Games SEK 104.2 million (-). > Net sales of Partner Publishing/Film business area amounted to SEK 429.0 million (435.6). > EBITDA increased by 137% to SEK 1,172.5 million (495.2), corresponding to an

Kemira adds capacity in Asia-Pacific to support the growing paper and board industry

Kemira, a global leader in sustainable chemical solutions for water intensive industries adds capacity in Asia-Pacific and announces the start-up of a new dry polymer production plant in Ulsan, South Korea and the initiation of planning for increased production capacity of sizing agents in Nanjing, China. These investments are part of Kemira’s growth strategy implementation and underline Kemira’s strong commitment to the paper and board customer base and support Kemira’s water treatment growth initiatives in the Asia-Pacific (APAC) region.   Kemira has opened a new dry polymer production

NOTICE OF EXTRAORDINARY GENERAL MEETING OF M.O.B.A. NETWORK AB (publ)

The shareholders of M.O.B.A. Network AB (publ) (the ”Company”), reg. no 559144-3964, are hereby invited to the Extraordinary General Meeting on Monday, June 7 2021. To counteract the spread of covid-19, the Board of Directors has decided that the Extraordinary General Meeting shall be conducted without the physical presence of shareholders, representatives, or outsiders and that the shareholders before the meeting shall have the opportunity to exercise their voting rights by post. RIGHT TO ATTEND The general meeting Shareholders who wish to participate in the meeting shall: i. be

M.O.B.A. Network AB (publ) carries out directed new issues of approximately SEK 110 million to finance the acquisition of Magic Find

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. INSIDER INFORMATION: The Board of M.O.B.A. Network AB (publ) ("MOBA Network" or "the Company") has based on the existing mandate granted by the Annual General Meeting held on

Cantargia reports positive results in ongoing phase IIa clinical trial in pancreatic cancer using nadunolimab and chemotherapy

Cantargia AB today announced positive results from the ongoing CANFOUR trial investigating nadunolimab (CAN04) in combination with gemcitabine/nab-paclitaxel (Abraxane[®]) for first line treatment of patients with advanced pancreatic cancer (PDAC). The efficacy analysis included 33 patients. Overall, the efficacy compares favorably to historical control data. Median iPFS was 7.8 months and other notable findings include five patients with durable benefit beyond initial progression (pseudoprogression), and an additional nine patients with confirmed partial response with a median duration of

Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology

STOCKHOLM — May 19, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that three abstracts with data on melflufen (INN melphalan flufenamide) in relapsed refractory multiple myeloma, RRMM, have been accepted by the 2021 American Society of Clinical Oncology, ASCO, and have now been published online. The clinical data presentations include updates on Oncopeptides’ ANCHOR and LIGHTHOUSE studies as well as a pooled analysis of the O-12-M1 and HORIZON studies in

Zalaris ASA acquires ba.se. GmbH to strengthen payroll and HR BPO for the retail industry

Zalaris ASA has agreed to acquire ba.se. service & consulting GmbH (“ba.se”), a leading provider of payroll and related HR services to the retail industry in Germany.ba.se had revenue of EUR 6.1 million for the year ended 30 September 2020. The transaction will be financed from available cash, and is expected to be accretive already in 2021. The purchase price consists of an up-front payment and a performance-based element. The transaction will close in Q2 2021, but will have key milestones for performance during the period 2021 to 2023. The deal joins two leading providers of payroll

CELLINK has entered into an agreement to acquire Nanoscribe, a market leading 3D bioprinting company based on Two-Photon Polymerization technology

CELLINK AB (publ) ("CELLINK") has entered into an agreement with the shareholders of Nanoscribe Holding GmbH ("Nanoscribe"), a market leading and award-winning German company focusing on development of high-precision 3D printers based on Two-Photon Polymerization technology (“2PP”), to acquire all outstanding shares on a cash- and debt-free basis, and under the assumption that the working capital at closing equals the normalized working capital, to a purchase price of €34 million and approximately €16 million in earn-outs, in Nanoscribe (the "Acquisition"). Approximately thirty-five percent

Salmon Evolution Holding ASA: Minutes of Annual General Meeting

Salmon Evolution Holding ASA (“Salmon Evolution” or the “Company”) has today held the 2021 annual general meeting (“AGM”) as called for on 4 May 2021. All resolutions were made in accordance with the proposals set out in the AGM notice, including a change of the Company’s name to Salmon Evolution ASA. Complete minutes from the AGM are attached to this notice and are also available on the Company’s website www.salmonevolution.no. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

New grants for early career researchers: applications open  1 August

The International Society for Research in Human Milk and Lactation and the Family Larsson-Rosenquist Foundation are recharging their annual grant offering for researchers who wish to enter or advance a career in human milk and lactation.TEP 2.0, the next generation of their Trainee Expansion Program (TEP) , offers a total of USD $1.25 million over five years, through two types of grant: Trainee Travel Fund (TTF) grants – up to USD $10,000 over up to three months to gain a new skill or experience in a different setting.   Trainee

MUSTI GROUP PLC: Share Repurchase 19.5.2021

Musti Group Stock Exchange Release 19.5.2021 MUSTI GROUP PLC: Share Repurchase 19.5.2021 In the NASDAQ OMX Helsinki Trade date           19.5.2021Bourse trade         BuyShare                  MUSTIAmount             10 000 SharesAverage price/ share    30,2119 EURTotal cost            302 119,00 EUR Company now holds a total of 140 000 sharesincluding the shares repurchased on 19.5.2021 On behalf of Musti Group Nordea Bank Finland Plc Janne Sarvikivi

There are no items matching the current filter
There are no more items matching the current filter
Back to top